TWiV 1333: STING like a nanoparticle, float like HIV

HIV-1 infection in resting T-cells relies on viral synapse formation, which initiates CD4-LCK signaling and activates CDK1. This kinase activity remodels the nuclear pore complex, enabling the viral capsid to bypass traditional barriers and enter the nucleus. Complementing this virological insight, a novel nanoparticle platform, Nano-CF501, targets the STING pathway to induce robust mucosal and systemic immunity against beta coronaviruses. This adjuvant significantly enhances dendritic cell activation and antigen uptake, resulting in durable, cross-reactive antibody and T-cell responses in both mouse and non-human primate models. Beyond these research findings, the discussion addresses the broader implications of laboratory supply chain instability, specifically the bankruptcy of major primate suppliers, and the logistical challenges of establishing local vaccine manufacturing infrastructure in resource-limited settings.